{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:55:17Z","timestamp":1776329717776,"version":"3.50.1"},"reference-count":18,"publisher":"Baskent University","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.6002\/ect.2024.0322","type":"journal-issue","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T07:08:09Z","timestamp":1763363289000},"source":"Crossref","is-referenced-by-count":0,"title":[],"prefix":"10.6002","volume":"23","member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Gatza E, Reddy P, Choi SW. Prevention and treatment of acute graft-versus-host disease in children, adolescents, and young adults. Biol Blood Marrow Transplant. 2020;26(5):e101-e112. doi:10.1016\/j.bbmt.2020.01.004","DOI":"10.1016\/j.bbmt.2020.01.004"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Bola\u00f1os-Meade J, Hamadani M, Wu J, et al; BMT CTN 1703 Investigators. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388(25):2338-2348. doi:10.1056\/NEJMoa2215943","DOI":"10.1056\/NEJMoa2215943"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Sheikh IN, Alqahtani S, Ragoonanan D, et al. Post-transplant cyclophosphamide after matched sibling and unrelated donor hematopoietic stem cell transplantation in pediatric patients with acute myeloid leukemia. Int J Mol Sci. 2022;23(15):8748. doi:10.3390\/ijms23158748","DOI":"10.3390\/ijms23158748"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Luznik L, O'Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39(6):683-693. doi:10.1053\/j.seminoncol.2012.09.005","DOI":"10.1053\/j.seminoncol.2012.09.005"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97(4):855-864. doi:10.1046\/j.1365-2141.1997.1112925.x","DOI":"10.1046\/j.1365-2141.1997.1112925.x"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129(1):30-37. doi:10.1182\/blood-2016-07-686642","DOI":"10.1182\/blood-2016-07-686642"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Cahn JY, Klein JP, Lee SJ, et al; Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle et Th\u00e9rapie Cellulaire; Dana Farber Cancer Institute; International Bone Marrow Transplant Registry. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle et Th\u00e9rapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. 2005;106(4):1495-1500. doi:10.1182\/blood-2004-11-4557","DOI":"10.1182\/blood-2004-11-4557"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956. doi:10.1016\/j.bbmt.2005.09.004","DOI":"10.1016\/j.bbmt.2005.09.004"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Toubai T, Sun Y, Reddy P. GVHD pathophysiology: is acute different from chronic? Best Pract Res Clin Haematol. 2008;21(2):101-117. doi:10.1016\/j.beha.2008.02.005","DOI":"10.1016\/j.beha.2008.02.005"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Oostenbrink LVE, Pool ES, Jol-van der Zijde CM, et al. Successful mismatched hematopoietic stem cell transplantation for pediatric hemoglobinopathy by using ATG and post-transplant cyclophosphamide. Bone Marrow Transplant. 2021;56(9):2203-2211. doi:10.1038\/s41409-021-01302-0","DOI":"10.1038\/s41409-021-01302-0"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. El Fakih R, Hashmi SK, Ciurea SO, Luznik L, Gale RP, Aljurf M. Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application. Bone Marrow Transplant. 2020;55(1):40-47. doi:10.1038\/s41409-019-0547-8","DOI":"10.1038\/s41409-019-0547-8"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Gooptu M, Bola\u00f1os-Meade J, Koreth J. Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond. Blood Rev. 2023;62:101053. doi:10.1016\/j.blre.2023.101053","DOI":"10.1016\/j.blre.2023.101053"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Mielcarek M, Furlong T, O'Donnell PV, et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood. 2016;127(11):1502-1508. doi:10.1182\/blood-2015-10-672071","DOI":"10.1182\/blood-2015-10-672071"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Wu KH, Weng TF, Li JP, Chao YH. Antithymocyte globulin plus post-transplant cyclophosphamide combination as an effective strategy for graft-versus-host disease prevention in haploidentical peripheral blood stem cell transplantation for children with high-risk malignancies. Pharmaceuticals (Basel). 2022;15(11):1423. doi:10.3390\/ph15111423","DOI":"10.3390\/ph15111423"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. DeZern AE, Brodsky RA. Combining PTCy and ATG for GvHD prophylaxis in non-malignant diseases. Blood Rev. 2023;62:101016. doi:10.1016\/j.blre.2022.101016","DOI":"10.1016\/j.blre.2022.101016"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. El-Cheikh J, Devillier R, Dulery R, e al. Impact of adding antithymocyte globulin to posttransplantation cyclophosphamide in haploidentical stem-cell transplantation. Clin Lymphoma Myeloma Leuk. 2020;20(9):617-623. doi:10.1016\/j.clml.2020.04.003","DOI":"10.1016\/j.clml.2020.04.003"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Holtick U, Chemnitz JM, Shimabukuro-Vornhagen A, et al. OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur J Haematol. 2016;96(1):27-35. doi:10.1111\/ejh.12541","DOI":"10.1111\/ejh.12541"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Ersoy GZ, Bozkurt C, Aksoy BA, et al. Evaluation of the risk factors for BK virus-associated hemorrhagic cystitis in pediatric bone marrow transplantation patients: Does post-transplantation cyclophosphamide increase the frequency? Pediatr Transplant. 2023;27(1):e14364. doi:10.1111\/petr.14364","DOI":"10.1111\/petr.14364"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:50:21Z","timestamp":1763376621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ectrx.org\/detail\/archive\/2025\/23\/10\/0\/665\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2024.0322","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}